New York City, NY: Pharmaceutical companies Pfizer, BioNTech, and Moderna are expected to generate billions of dollars in revenue from the sale of the COVID-19 vaccine.

According to analysts and healthcare investors, this figure could rival the flu vaccine market, with annual sales of $ 6 billion.

Fully vaccinated people will need additional vaccination to maintain long-term protection and fend off new coronavirus variants, according to people familiar with the three companies.

Many governments, including Chile, Germany and Israel, are providing booster immunity to older people and people with weak immunity to combat the delta mutation.

A booster dose of the Pfizer and Modana vaccines for people with a weakened immune system was approved by the US Food and Drug Administration on Thursday.

Pfizer and its German partner BioNTech, along with Moderna, recorded over $ 60 billion in revenue in 2021 and 2022, respectively, with analysts at over $ 6.6 billion in Pfizer / BioNTech shots and in Moderna in 2023. We forecast revenue of over $ 7.6 billion. amount of sales.

The World Health Organization has urged governments around the world to delay booster shots until more people are able to receive the first two vaccinations.

Pfizer and Moderna may have greater pricing power over boosters until competitors catch up. Pfizer initially charged $ 19.50 each time in the US and € 19.50 in the EU, but raised these prices by 24% and 25%, respectively.

Both AstraZeneca and Johnson & Johnson are collecting additional data on the use of vaccines as boosters, but vaccines from Novavax, Curevac, and Sanofi, which have not yet been approved, may also be approved for use.

Mixed booster doses have already been tested by the National Institute for Allergic Infectious Diseases and no other country has reported any issues with this strategy.

Bijan Salehizadeh, managing director of healthcare investment firm Navimed Capital, said the U.S. government could continue to pay to maintain high vaccination rates and prevent a surge in new COVID-19, especially under democratic regimes. Said that was high.